94212-06-3

Upstream product

• 2620-84-0 2-(4-methoxyphenyl)-1-phenyl-1H-benzo[d]imidazole 
• 123-08-0 4-hydroxy-benzaldehyde 
• 534-85-0 N-phenyl-1,2-benzenediamine 
• 100-07-2 4-methoxy-benzoyl chloride 

Downstream Products

• 175713-97-0 1-phenyl-2-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-benzo[d]imidazole 
• 175713-98-1 1-phenyl-2-[4-[3-(piperidin-1-yl)propoxy]phenyl]-benzimidazole 

Relevant academic research and scientific papers

Dendritic iridium complex electroluminescent material capable of solution processing and synthetic method thereof

The invention discloses a dendritic iridium complex electroluminescent material capable of solution processing and a synthetic method thereof. The molecular structure consists of two parts, one part is an iridium complex with room temperature phosphorescence property as a luminescent core, the other part is a racial with high triplet state energy level as a peripheral branch radial, and the two parts are connected through a non-conjugated radical. The molecule is of the structure as shown in the specification, wherein C1 to C3 are ionic dendritic iridium complexes, and C4 to C6 are neutral dendritic iridium complexes of similar structure. R1 and R2 are high triplet state energy level radicals with non-conjugated radical ends. The problems of synthesis, purification, device preparation technology and cost, existing in wet process preparation devices, of iridium complex materials can be solved.

Conventional and microwave-assisted synthesis of benzimidazole derivatives and their in vitro inhibition of human cyclooxygenase

A large series of 1,2-diaryl-benzimidazole and 2-aryl-1H-benzimidazole derivatives were synthesized with slight differences using both microwave irradiation and conventional heating methods. Usually higher yields and time reactions reduction were obtained

Methods of treating or preventing interstitial cystitis

PCT No. PCT/US97/03895 Sec. 371 Date Aug. 25, 1998 Sec. 102(e) Date Aug. 25, 1998 PCT Filed Mar. 7, 1997 PCT Pub. No. WO97/33873 PCT Pub. Date Sep. 18, 1997This invention provides methods for the treatment or prevention of interstitial cystitis or urethral syndrome in a mammal which comprise administering to a mammal in need thereof an effective amount of a substituted benzimidazole, or a pharmaceutically acceptable salt or solvate thereof.

Methods of treating or preventing sleep apnea

This invention provides methods for the treatment or prevention of sleep apnea in a mammal which compris administering to a mammal in need thereof an effective amount of a substituted benzimidazole, or a pharmaceutically acceptable salt or solvate thereof.

Non-peptidyl tachykinin receptor antagonists

This invention provides novel substituted benzimidazoles of formula II which are useful as tachykinin receptor antagonists. This invention also provides methods for treating a condition associated with an excess of tachykinin which comprises administering to a mammal in need thereof one of a series of substituted benzimidazoles. This invention further provides pharmaceutical formulations comprising one or more of the substituted benzimidazoles of the present invention in association with pharmaceutical carriers, diluents, or excipients. A and Ra-Re are as defined in the description.

METHODS FOR TREATING A PHYSIOLOGICAL DISORDER ASSOCIATED WITH BETA-AMYLOID PEPTIDE

This invention provides substituted benzimidazoles which are useful in treating or preventing conditions associated with beta-amyloid peptide. Some such conditions associated with beta-amyloid peptide include Alzheimer's Disease, Down's Symdrome and amyloidosis of the Dutch type